Neurol. praxi. 2019;20(4):307-311 | DOI: 10.36290/neu.2019.133

Uncontrolled seizures in adult epilepsy patients

MUDr. Jana Zárubová1,2, prof. MUDr. Petr Marusič, Ph.D.1
1 Neurologická klinika 2. LF UK a FN Motol, Praha
2 Neurologie, Medicon, a. s., Praha

There are still patients with epilepsy and uncontrolled seizures despite established treatment. It is dangerous, the risks depend on the type of seizure. It could be health and life-threatening. A refractory epilepsy may progressively impair brain structure and function. Patients are at higher risk of comorbidities, including injuries and accidents, higher mortality and psychosocial consequences. The goal of treatment is a patient without seizures. Only remission (5 years without seizures) reduces the described risks to the level of the general population. The task of the neurologist is to review the examinations and treatments selected so far, to plan the next management with which the patient and/or his/her legal guardian is familiar. The documentation must include a working balance sheet and AEDs gradual testing plan, or other treatments. In a patient with persistent seizures, the documentation must show an effort to classify their type, determine the cause of epilepsy and its type, eventually epileptic syndrome. It is necessary to search for, confirm or eliminate known comorbidities, because preventative measures can prohibit their formation. In the case of already confirmed comorbidities, we treat them, if necessary in cooperation with specialists from other fields and the general practitionar. There are models for predicting pharmacoresistance that can be used by clinicians. Current epileptology is proactive and seeks to protect patients quality life years. One of the most important factor in a good therapeutic relationship between neurologist/patient with epilepsy is trust and the hope that there is still much to offer.

Keywords: pharmacoresistent epilepsy, uncontrolled seizures, comorbidities, mortality

Published: September 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zárubová J, Marusič P. Uncontrolled seizures in adult epilepsy patients. Neurol. praxi. 2019;20(4):307-311. doi: 10.36290/neu.2019.133.
Download citation

References

  1. Hughes DM, Bonnett LJ, Czanner G, Komárek A, Marson AG, García-Fi?ana M. Identification of patients who will not achieve seizure remission within 5 years on AEDs. Neurology 2018; 91(22): e2035-e2044. Go to original source... Go to PubMed...
  2. Hughes DM, Bonnett LJ, Marson AG, García-Fi?ana M. Identifying patients who will not reachieve remission after breakthrough seizures. Epilepsia 2019; 60: 774-782. Go to original source... Go to PubMed...
  3. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069-1077. Go to original source... Go to PubMed...
  4. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011; 365(10): 919-926. Go to original source... Go to PubMed...
  5. Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014; 37: 59-70. Go to original source... Go to PubMed...
  6. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369(9566): 1000-1015. Go to original source... Go to PubMed...
  7. Marusič P, Zárubová J. Mechanismy účinku antiepileptik a jejich význam v klinické praxi. Neurol. praxi 2019; 20(2): 150-152. Go to original source...
  8. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51(5): 1256-1262. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.